Vedolizumab Monotherapy Vs Combination Therapy With Tacrolimus in UC
Status:
Terminated
Trial end date:
2019-01-31
Target enrollment:
Participant gender:
Summary
The aim of this study is to assess if a combination therapy of tacrolimus and vedolizumab is
superior to vedolizumab monotherapy for induction of remission in moderate to severe UC, and
its effect on long and short-term outcomes including colectomy rate. Secondary aim of this
study is to assess the safety of tacrolimus as an induction agent in patients with UC.
Phase:
Phase 3
Details
Lead Sponsor:
Medical College of Wisconsin
Collaborators:
Bnai Zion Medical Center Takeda
Treatments:
Sulfamethoxazole Tacrolimus Trimethoprim Trimethoprim, Sulfamethoxazole Drug Combination Vedolizumab